Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Revenues [+] | 10,981.7 | 13,444.6 | 14,377.9 | 13,452.9 | 12,273.9 | 11,448.8 | 10,763.8 | 9,703.3 |
Products | | | | | | | 9,188.5 | 8,203.4 |
Other | | | | | | | 236.1 | 304.5 |
Revenue growth | -18.3% | -6.5% | 6.9% | 9.6% | 7.2% | 6.4% | 10.9% | 40.0% |
Cost of goods sold | 2,991.0 | 2,270.0 | 2,445.3 | 2,563.6 | 2,444.7 | 1,864.3 | -1,240.4 | -1,171.0 |
Gross profit | 7,990.7 | 11,174.6 | 11,932.6 | 10,889.3 | 9,829.2 | 9,584.5 | 12,004.2 | 10,874.3 |
Gross margin | 72.8% | 83.1% | 83.0% | 80.9% | 80.1% | 83.7% | 111.5% | 112.1% |
Selling, general and administrative | 2,674.3 | 2,504.5 | 2,374.7 | 2,106.3 | 1,933.9 | 1,946.6 | 2,113.1 | 2,232.3 |
Research and development | 2,501.2 | 3,990.9 | 2,280.6 | 2,597.2 | 2,253.6 | 1,973.3 | 2,012.8 | 1,893.4 |
Equity in earnings | | | | | | | 12.5 | 15.1 |
Other operating expenses | 7.2 | 140.4 | 296.9 | 185.0 | 112.3 | 10.2 | 2,863.4 | 2,798.3 |
EBITDA [+] | 3,295.7 | 4,996.0 | 7,445.1 | 6,651.3 | 6,610.4 | 6,337.1 | 5,627.8 | 4,653.5 |
EBITDA growth | -34.0% | -32.9% | 11.9% | 0.6% | 4.3% | 12.6% | 20.9% | 53.1% |
EBITDA margin | 30.0% | 37.2% | 51.8% | 49.4% | 53.9% | 55.4% | 52.3% | 48.0% |
Depreciation and amortization | 487.7 | 457.2 | 464.7 | 650.5 | 1,081.0 | 682.7 | 217.8 | 198.3 |
EBITA | 2,808.0 | 4,538.8 | 6,980.4 | 6,000.8 | 5,529.4 | 5,654.4 | 5,410.0 | 4,455.2 |
EBITA margin | 25.6% | 33.8% | 48.5% | 44.6% | 45.1% | 49.4% | 50.3% | 45.9% |
Amortization of intangibles | | | | | | | 382.6 | 489.8 |
EBIT [+] | 2,808.0 | 4,538.8 | 6,980.4 | 6,000.8 | 5,529.4 | 5,654.4 | 5,027.4 | 3,965.4 |
EBIT growth | -38.1% | -35.0% | 16.3% | 8.5% | -2.2% | 12.5% | 26.8% | 58.2% |
EBIT margin | 25.6% | 33.8% | 48.5% | 44.6% | 45.1% | 49.4% | 46.7% | 40.9% |
Non-recurring items [+] | -32.7 | -11.3 | -62.2 | 112.2 | 183.6 | 502.7 | 123.9 | -22.1 |
Loss (gain) on sale of assets | | | | | | | | 16.8 |
Unusual expense | -50.7 | -86.3 | -63.7 | -12.3 | 62.7 | 14.8 | 30.5 | -38.9 |
Legal settlement | | | | | | 454.8 | | |
In-process research & development | 18.0 | 75.0 | | 112.5 | 120.0 | | | |
Interest expense, net [+] | -11.0 | -42.0 | -120.0 | -112.5 | -78.5 | -63.4 | -22.1 | -12.2 |
Interest expense | 253.6 | 222.5 | 187.4 | 200.6 | 250.8 | 260.0 | 95.5 | 29.5 |
Interest income | 11.0 | 42.0 | 120.0 | 112.5 | 78.5 | 63.4 | 22.1 | 12.2 |
Other income (expense), net [+] | -852.9 | 677.9 | 150.7 | 99.1 | -44.7 | -22.1 | -62.8 | -23.6 |
Other | | | | | | | | -25.8 |
Pre-tax income | 1,745.2 | 5,047.5 | 7,125.9 | 5,899.6 | 5,128.8 | 4,933.0 | 4,767.3 | 3,946.6 |
Income taxes | 52.5 | 992.3 | 1,158.0 | 1,425.6 | 2,458.7 | 1,237.3 | 1,161.6 | 989.9 |
Tax rate | 3.0% | 19.7% | 16.3% | 24.2% | 47.9% | 25.1% | 24.4% | 25.1% |
Minority interest | 171.5 | 59.9 | | 43.3 | 131.0 | -7.1 | 46.2 | 6.8 |
Net income | 1,556.1 | 4,000.6 | 5,888.5 | 4,430.7 | 2,539.1 | 3,702.8 | 3,547.0 | 2,934.8 |
Net margin | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% | 33.0% | 30.2% |
|
Basic EPS [+] | $10.44 | $24.86 | $31.47 | $21.62 | $11.94 | $16.95 | $15.37 | $12.41 |
Growth | -58.0% | -21.0% | 45.5% | 81.1% | -29.6% | 10.3% | 23.8% | 57.9% |
Diluted EPS [+] | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.92 | $15.34 | $12.37 |
Growth | -58.1% | -21.1% | 45.6% | 81.0% | -29.6% | 10.3% | 24.0% | 58.3% |
|
Dividends per share [+] | | | | $0.18 | $1.42 | | | |
Growth | | | -100.0% | -87.5% | | | | |
|
Shares outstanding (basic) [+] | 149.1 | 160.9 | 187.1 | 204.9 | 212.6 | 218.4 | 230.7 | 236.4 |
Growth | -7.3% | -14.0% | -8.7% | -3.6% | -2.7% | -5.3% | -2.4% | -0.2% |
Shares outstanding (diluted) [+] | 149.6 | 161.3 | 187.4 | 205.3 | 213.0 | 218.8 | 231.2 | 237.2 |
Growth | -7.3% | -13.9% | -8.7% | -3.6% | -2.7% | -5.4% | -2.5% | -0.5% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|